Postgrad LIVE! Study Fairs

Bristol

University of Leeds Featured PhD Programmes
University of Huddersfield Featured PhD Programmes
University of Warwick Featured PhD Programmes
FindA University Ltd Featured PhD Programmes
University of Reading Featured PhD Programmes

Targeting hematological malignancies using fragment-based drug design

This project is no longer listed in the FindAPhD
database and may not be available.

Click here to search the FindAPhD database
for PhD studentship opportunities
  • Full or part time
    Dr V Veverka
    Dr P M Rezacova
  • Application Deadline
    No more applications being accepted
  • Competition Funded PhD Project (Students Worldwide)
    Competition Funded PhD Project (Students Worldwide)

Project Description

The project will be focused on the knowledge-based design of active compounds targeting several proteins or protein-protein interactions, which are implicated in the development of hematological malignancies. The compounds will be developed using the fragment-based approach. The work on this project provides the opportunity to acquire an expertise in protein biochemistry, biophysics and structural biology, as well as to get an insight into the rational drug design process through a close collaboration with the medicinal and computational chemists.

How to apply

To apply for a PhD study at IOCB Prague, you must hold a Master’s degree (MSc) or the equivalent of the MSc in similar field (four or five year undergraduate degree). The application can be submitted before obtaining the Master’s degree, however, the applicant should obtain the degree within five months after the application deadline.

For more information visit our website “Call for PhD applications 2019”:
https://www.uochb.cz/web/structure/797.html

You can apply online via our application form http://www.uochb.cz/phdapplication/index.php/PhDrecruitment

Funding Notes

Regular monthly income of students at IOCB Prague varies depending on the faculty scholarship and supervisor's financial options.

References

1. Hnizda, A., et al.,Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation. Leukemia 2018, 32 (6), 1393.
2. Čermáková, K., et al., Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia. Cancer Research, 2014. 74 (18): 5139

Related Subjects



FindAPhD. Copyright 2005-2019
All rights reserved.